Let just tell you right now, PPHM is going to sky rocket! Have you read the latest news?
Peregrine
Pharmaceuticals Receives FDA Fast Track Designation for Its
Immunotherapy Bavituximab as a Potential Treatment of Second-Line
Non-Small Cell Lung Cancer
This companies stock is going to reach new heights. Well, at least it looks good on paper.
About PPHM
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a
portfolio of innovative monoclonal antibodies in clinical trials
focused on the treatment and diagnosis of cancer. We are pursuing multiple clinical programs
in cancer with our lead product candidate bavituximab and novel brain
cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing
capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers.
For oncology indications, our
lead PS-targeting candidate bavituximab in combination with
chemotherapy has demonstrated promising signs of anti-tumor activitiy
and survival trends in patients with non-small cell lung cancer (NSCLC)
and advanced breast cancer.
